Literature DB >> 17760931

Eye complications of cetuximab therapy.

B Melichar1, I Nemcová.   

Abstract

Skin toxicity is the most important side effect of cetuximab administration, but little is known about the eye toxicity, including periorbital skin. We present here four cases of patients with metastatic colorectal carcinoma treated with the combination of cetuximab, irinotecan, 5-fluorouracil and leucovorin who had manifestation of complications in the eye or periorbital skin. These manifestations consisted of erythematous eruptions in the periorbital skin with blepharitis and conjunctivitis in three patients and trichomegaly in one patient. The symptoms were controlled with local therapy including corticosteroids and antibiotics. The skin toxicity in the periorbital region is more important than in other skin areas because of the impact on the social activity of the patient and the vision. The manifestations of eye toxicity of cetuximab may be controlled by local therapy, and the management of these patients requires the collaboration of medical oncologist and ophthalmologist.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760931     DOI: 10.1111/j.1365-2354.2006.00763.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  12 in total

1.  Eyelash trichomegaly secondary to panitumumab therapy.

Authors:  L G T Morris; H S Hochster; M D Delacure
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

Review 2.  Neopterin as a biomarker of immune response in cancer patients.

Authors:  Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová
Journal:  Ann Transl Med       Date:  2017-07

Review 3.  FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.

Authors:  Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Pavel Soucek
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 4.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

5.  Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Authors:  Durga S Borkar; Mario E Lacouture; Surendra Basti
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

Review 6.  Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Debabrata Mukhopadhyay; Priyabrata Mukherjee
Journal:  Adv Drug Deliv Rev       Date:  2009-11-13       Impact factor: 15.470

Review 7.  Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.

Authors:  L Peuvrel; C Bachmeyer; Z Reguiai; J B Bachet; T André; R J Bensadoun; O Bouché; M Ychou; B Dréno
Journal:  Support Care Cancer       Date:  2012-02-24       Impact factor: 3.359

8.  Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes.

Authors:  Vinayak V Maka; Hithashree Rajanna; Anil Kumar Narasiyappah; Rohith Chitrapur; Nalini Kilara
Journal:  Oxf Med Case Reports       Date:  2014-08-05

9.  Use of amniotic membrane graft in the surgical management of cicatricial ectropion associated with cetuximab therapy.

Authors:  Kateki Vinod; Vicente Diaz
Journal:  J Surg Case Rep       Date:  2015-01-08

10.  Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor.

Authors:  Hana Študentová; Jarmila Indráková; Pavla Petrová; Milan Kamínek; Hana Kalábová; Vlastislav Šrámek; Tomáš Adam; Bohuslav Melichar
Journal:  Oncol Lett       Date:  2015-12-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.